Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer.

Stephanie B Wheeler,Jason Rotter,Anagha Gogate,Katherine E Reeder-Hayes,Sarah W Drier,Donatus U Ekwueme,Temeika L Fairley,Gabrielle B Rocque,Justin G Trogdon

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 3|浏览14

暂无评分

摘要

In this setting where multiple single-agent chemotherapy options are recommended by clinical guidelines and share similar survival and adverse event trajectories, treatment sequencing approaches that minimize costs early may improve the value of care.

查看译文

关键词

metastatic breast cancer,breast cancer,pharmacologic treatment options,cost-effectiveness,endocrine-refractory,triple-negative

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要